This company listing is no longer active
ESP Stock Overview
Esperite N.V., together with its subsidiaries, operates as a regenerative and predictive medicine company in the Netherlands, Spain, Italy, Switzerland, and internationally.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Esperite N.V. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €0.0092 |
52 Week High | €0.032 |
52 Week Low | €0.009 |
Beta | 0 |
1 Month Change | -22.03% |
3 Month Change | -56.60% |
1 Year Change | -66.67% |
3 Year Change | -82.34% |
5 Year Change | -98.37% |
Change since IPO | -99.87% |
Recent News & Updates
Recent updates
Shareholder Returns
ESP | NL Biotechs | NL Market | |
---|---|---|---|
7D | 0% | -1.2% | 0.06% |
1Y | -66.7% | -5.7% | 19.1% |
Rendite im Vergleich zur Industrie: ESP underperformed the Dutch Biotechs industry which returned -19.8% over the past year.
Rendite vs. Markt: ESP underperformed the Dutch Market which returned -27.8% over the past year.
Price Volatility
ESP volatility | |
---|---|
ESP Average Weekly Movement | 14.4% |
Biotechs Industry Average Movement | 7.5% |
Market Average Movement | 3.7% |
10% most volatile stocks in NL Market | 7.8% |
10% least volatile stocks in NL Market | 2.3% |
Stabiler Aktienkurs: ESP's share price has been volatile over the past 3 months.
Volatilität im Zeitverlauf: ESP's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Dutch stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2000 | n/a | Frédéric Amar | https://www.esperite.com |
Esperite N.V. Fundamentals Summary
ESP fundamental statistics | |
---|---|
Market cap | €481.41k |
Earnings (TTM) | -€18.72m |
Revenue (TTM) | €13.57m |
0.0x
P/S Ratio0.0x
P/E RatioIs ESP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ESP income statement (TTM) | |
---|---|
Revenue | €13.57m |
Cost of Revenue | €4.50m |
Gross Profit | €9.07m |
Other Expenses | €27.78m |
Earnings | -€18.72m |
Last Reported Earnings
Jun 30, 2018
Next Earnings Date
n/a
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did ESP perform over the long term?
See historical performance and comparison